Welcome back to Business Trip by PsyMed Ventures, a podcast exploring the future of mental and brain health & the startups building it! 🧠
Matias interviews James (Jim) Gorman MD PhD from the Wyss Institute. Jim is Principal Investigator on the Wyss Institute Brain Targeting Program (BTP). Jim leads a team developing new approaches to transport drugs through the blood brain barrier (BBB) into the CNS.
In this episode, we discuss:
Why the BBB blocks most modern drugs from entering the brain, creating the biggest bottleneck in neuro
How brain shuttles hijack natural transport pathways like the transferrin receptor to move drugs across the BBB
How new modalities that reach the brain can potentially treat diseases like Alzheimer’s, Parkinson’s, ALS, and lysosomal disorders
Why delivery route of shuttles enable IV or subcutaneous dosing instead of invasive intrathecal injections
How early data shows that shuttle-enabled antibodies clear amyloid faster, at lower doses, and with fewer side effects
How the field is accelerating through a pre-competitive consortium model that lets multiple companies share shuttle platforms
Listen to the episode here, on Spotify, or on Apple Podcasts.
Once you’ve finished the episode, we’d love to hear your thoughts! Tweet us at @psymedventures or email us at hi@psymed.ventures to share your views.
P.S. Do you know someone who would enjoy the Business Trip by PsyMed Ventures podcast? Feel free to share this newsletter by clicking the link below and hitting the ❤️ button on this post to help us reach more people on Substack 🙏
No posts
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.